en · de · es · fr · pt
bench-notes.peptides6088.com › Guide › Research And Regulatory Status — Hands-On Walkthrough

Research And Regulatory Status — Hands-On Walkthrough

By Editorial Desk · published 2026-03-13 · last reviewed 2026-04-08 · Guide

Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-04-08. Numbers and descriptions here follow the published literature rather than marketing material.

Research and Regulatory Status

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Related pages on this site

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Further detail

German Doner Kebab (GDK) is a fast casual kebab chain, specialising in German doner kebabs, owned by Hero Brands since 2017. Tracing its heritage to a restaurant in Berlin in 1989, the first site opened in Dubai by Farshad Abbaszadeh and his wife Leila Zomorrodian in 2013. The company was purchased with a majority share in 2017 by Hero Brands and moved its headquarters to Glasgow. The company operates more than 160 restaurants throughout the United Kingdom, Sweden, North America and the Middle East.

=== Disease association === Genetic variants and haplotypes (i.e., allotypes) of ERAP1 have been associated with a wide variety of inflammatory conditions, infectious diseases, and cancer. In particular, ERAP1 is a major risk gene identified in genome-wide association studies of MHC-I associated inflammatory conditions (or "MHC-I-opathies"), including Ankylosing Spondylitis, Bechet's disease, Birdshot Uveitis, and Psoriasis. In these conditions, ERAP1 is often in epistasis with the primary risk MHC-I allele. Other disease associations include insulin dependent Diabetes Mellitus and Multiple Sclerosis. Historically, ERAP1 gene associations were first reported in Hypertension. Emerging evidence links ERAP1 SNVs to cancer development, and susceptibility to infectious disease, such as ERAP1 SNVs that modify the resistance to influenza virus infection.

In 1899, he showed that negative electricity created by ultraviolet light landing on a metal (known now as the photoelectric effect) has the same mass-to-charge ratio as cathode rays; then he applied his previous method for determining the charge on ions to the negative electric particles created by ultraviolet light. By this combination he showed that electron's mass was 0.0014 times that of hydrogen ions. These "corpuscles" were so light yet carried so much charge that Thomson concluded they must be the basic particles of electricity, and for that reason other scientists decided that these "corpuscles" should instead be called electrons following an 1894 suggestion by George Johnstone Stoney for naming the basic unit of electrical charge. In 1904, Thomson published a paper describing a new model of the atom. Electrons reside within atoms, and they transplant themselves from one atom to the next in a chain in the action of an electrical current. When electrons do not flow, their negative charge logically must be balanced out by some source of positive charge within the atom so as to render the atom electrically neutral. Having no clue as to the source of this positive charge, Thomson tentatively proposed that the positive charge was everywhere in the atom, the atom being shaped like a sphere—this was the mathematically simplest model to fit the available evidence (or lack of it). The balance of electrostatic forces would distribute the electrons throughout this sphere in a more or less even manner.

Sources: en.wikipedia.org

Supporting material

There are two commonly cultivated strains which are known to be distinct. One is the strain that was collected in 1962 by ecologist and psychologist Sterling Bunnell (the Bunnell strain), colloquially mis-attributed as the Wasson-Hofmann strain. The other was collected from Huautla de Jiménez in 1991 by anthropologist Bret Blosser (the Blosser or Palatable strain). There are other strains that are not as well documented, such as the Luna strain (possibly Bunnell) isolated from a Hawaiian patch of Salvia divinorum clones, featuring unusually serrated and rounded rather than ovate leaves.

==== Self-assembled recombinant spider silk nanomembranes ==== Gustafsson et al. demonstrated free‐standing, bioactive membranes of cm-sized area, but only 250 nm thin, that were formed by self‐assembly of spider silk at the interface of an aqueous solution. The membranes uniquely combine nanoscale thickness, biodegradability, ultrahigh strain and strength, permeability to proteins and promote rapid cell adherence and proliferation. They demonstrated growing a coherent layer of keratinocytes. These spider silk nanomembranes have also been used to create a static in-vitro model of a blood vessel.

Dried fruit is fruit from which the majority of the original water content has been removed prior to cooking or being eaten on its own. Drying may occur either naturally, by sun, through the use of industrial dehydrators, or by freeze drying. Dried fruit has a long tradition of use dating to the fourth millennium BC in Mesopotamia, and is valued for its sweet taste, nutritional content, and long shelf life. In the 21st century, dried fruit consumption is widespread worldwide. Nearly half of dried fruits sold are raisins, followed by dates, prunes, figs, apricots, peaches, apples, and pears. These are referred to as "conventional" or "traditional" dried fruits: fruits that have been dried in the sun or in commercial dryers. Many fruits, such as cranberries, blueberries, cherries, strawberries, and mango are infused with a sweetener (e.g., sucrose syrup) prior to drying. Some products sold as dried fruit, like papaya, kiwifruit and pineapple, are most often candied fruit.

Sources: en.wikipedia.org

Supporting material

=== Victims === On 17 September 2008, Health Minister Chen Zhu stated tainted milk formula had "sickened more than 6,200 children, and that more than 1,300 others, mostly newborns, remain hospitalized with 158 suffering from acute kidney failure". By 23 September, about 54,000 children were reported to be sick and four had died. An additional 10,000 cases were reported from the provinces by 27 September. A World Health Organization official said 82% of the children made ill were 2 years of age or below. The Hong Kong Centre for Food Safety said that 99 per cent of the victims were aged under 3 years. Ten Hong Kong children were diagnosed with kidney problems, at least four cases were detected in Macau, and six in Taiwan. Non-human casualties included a lion cub and two baby orangutans which had been fed Sanlu infant formula at Hangzhou Zoo. The government said on 8 October it would no longer issue updated figures "because it is not an infectious disease, so it's not absolutely necessary for us to announce it to the public". Reuters compiled figures reported by local media across the country, and said the toll stood at nearly 94,000 at the end of September, excluding municipalities. Notably, 13,459 children had been affected in Gansu, Reuters quoted Xinhua saying Henan had reported over 30,000 cases, and Hebei also had nearly 16,000 cases. In late October, the government announced health officials had surveyed 300,000 Beijing families with children less than 3 years old.

Non-selective beta-blockers: propranolol, nadolol, timolol Beta-1-selective beta-blockers: atenolol, bisoprolol, metoprolol, esmolol Beta-blockers with vasodilating effect: labetalol, carvedilol, nebivolol Beta-blockers with intrinsic sympathomimetic activity: acebutolol, pindolol Some common side effects include increased airway resistance for non-selective beta-blockers, exacerbation of peripheral vascular diseases, and hypotension Beta-blockers are contraindicated in patients with second- or third-degree atrioventricular block. In particular, beta-blockers with intrinsic sympathomimetic activity are contraindicated in patients with myocardial infarction, heart failure or severe bradycardia. Beta-blockers should be used with caution in patients with asthma or chronic obstructive pulmonary disease (COPD) due to bronchoconstriction, and in patients with diabetes mellitus (DM) due to masking of hypoglycaemia.

=== Financial system === Market capitalization of U.S. banks lost a combined $100 billion in two days and European banks lost $50 billion. SVB's losses highlighted the challenge that banks could face as interest rate increases reduced the market value of bonds that they purchased under low-rate policies. Some companies have sought safety with larger commercial banks, transferring their deposits out from regional banks similar to Silicon Valley Bank, raising concerns about further instability in the banking sector. Several banks, such as First Republic Bank and Western Alliance Bancorporation, issued press releases seeking to calm investors. Despite these concerns, banking experts believe that other banks will remain stable as SVB was overly specialized in providing banking to a risky sector of the economy, and financial regulations have strengthened since the 2008 financial crisis, which preceded the Great Recession. SVB had, in 2021, reached the threshold under the Dodd-Frank Act requiring it to submit a resolution plan ("living will") to the FDIC, which it did the following year. It had not participated in periodic stress testing under the act, as the threshold for that requirement had been raised in 2018 under EGRRCPA; SVB's chief executive was among those requesting the change. On March 12, 2023, Signature Bank was also closed, being taken into possession by the New York State Department of Financial Services. Following the bank failures, the Federal Reserve announced the creation of a Bank Term Funding Program to shore up liquidity for other at-risk banks.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

How should AOD-9604 be stored?

Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.

Network